Other languages Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-13 pm EDT			5-day change	1st Jan Change
10.78 ^USD	+6.94%		-4.77%	+296.32%

Jun. 10	Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program	CI
Jun. 10	Skye Bioscience to stop eye disease drug development after failing mid-stage study	RE

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program	Jun. 10
Skye Bioscience to stop eye disease drug development after failing mid-stage study	Jun. 10
Skye Bioscience to discontinue development of eye disease treatment	Jun. 10
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22
Skye Bioscience Announces Board Changes	Mar. 04
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	Feb. 26
Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab	Dec. 11
Skye Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Skye Bioscience, Inc. Announces Board Appointments	23-09-01
Skye Bioscience, Inc. acquired Bird Rock Bio, Inc. for $15.6 million.	23-08-20
Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Skye Bioscience, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30
Skye Bioscience, Inc. Announces Board Changes	23-03-27
Skye Bioscience, Inc. Announces Resignation of Bobby Rai as a Member of the Board of Directors and the Nominating and Corporate Governance Committee of the Board	23-02-22
Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors	23-02-16
Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma	23-01-24
Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board	23-01-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Other languages

Filters